XML 48 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Collaboration Agreements - Additional Information (Detail)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Sep. 27, 2018
USD ($)
Milestone
Jun. 30, 2019
USD ($)
shares
May 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Mar. 31, 2020
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
Feb. 28, 2019
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Recognition of revenue         $ 100 $ 338      
Current deferred revenue         445     $ 544  
Pre-Funded Warrants                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Warrants to purchase shares of common stock | shares   2,548,117              
Common Stock                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of shares sold | shares   6,340,771              
Ginkgo Collaboration                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Prepayment to related party for collaboration agreement   $ 30,000              
Related party transaction collaboration agreement, initial term   5 years              
Current pre-paid research and development         11,300        
Non-current pre-paid research and development         12,400        
Ginkgo Collaboration | Pre-Funded Warrants                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Warrants to purchase shares of common stock | shares   2,548,117              
Ginkgo Collaboration | Common Stock                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of shares sold | shares   6,340,771              
AbbVie Agreement                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Number of mile stone payments under second phase | Milestone 2                
Initial milestone payment upon execution of amendment $ 2,000                
Increase in transaction price of performance obligation of second phase $ 2,000                
Cumulative catch-up adjustment to revenue, contract modification             $ 1,800    
Remaining milestone achieved                 $ 2,500
Recognition of revenue         100 $ 300      
Current deferred revenue         400        
AbbVie Agreement | IBDCo                  
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                  
Upfront non-refundable payment       $ 2,000          
Potential milestone payment         $ 16,500        
Collaboration in research and development         54 months        
Milestone payment     $ 2,000